BRIEF COMMUNICATION

Endogenous ZAP affects Zika virus RNA interactome

Ahmad Jawad Sabir[1,a], Nguyen Phuong Khanh Le[2,a], Prince Pal Singh[2,3,a], Uladzimir Karniychuk[2,*]

[1]Department of Microbiology and Immunology, University of Illinois, College of Medicine, Chicago, IL, USA

[2]Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA

[3]School of Public Health, University of Saskatchewan, Saskatoon, Canada

[a]**:** These authors contributed equally

* Correspondence: Uladzimir Karniychuk
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA
karniychuk.1@osu.edu

Abstract

One of the most recent advances in the analysis of viral RNA–cellular protein interactions is the Comprehensive Identification of RNA-binding Proteins by Mass Spectrometry (ChIRP-MS). Here, we used ChIRP-MS in mock-infected and Zika-infected wild-type cells and cells knockout for the zinc finger CCCH-type antiviral protein 1 (ZAP). We characterized "ZAP-independent" and "ZAP-dependent" cellular protein interactomes associated with flavivirus RNA and found that ZAP affects cellular proteins associated with Zika virus RNA. The ZAP-dependent interactome identified with ChIRP-MS provides potential ZAP co-factors for antiviral activity against Zika virus and possibly other viruses. Identifying the full spectrum of ZAP co-factors and mechanisms of how they act will be critical to understanding the ZAP antiviral system and may contribute to the development of antivirals.

Keywords: Flavivirus, Zika virus, Japanese encephalitis virus, West Nile virus, Zinc finger antiviral protein, ZAP, RNA, RNA helicase, interactome

INTRODUCTION

Emerging flaviviruses constantly threaten public health. The National Institute of Allergy and Infectious Diseases classifies flaviviruses—Zika virus, Japanese encephalitis virus (JEV), yellow fever virus (YFV), and West Nile virus (WNV) as a "Category B Priority," the 2nd highest priority of emerging pathogens and biodefense threats. Zika virus caused the human epidemic in 2015 and persists in at least 89 countries. Japanese encephalitis virus causes encephalitis in humans in the Asia-Pacific region [1], with 68,000 annual cases and 15,000 deaths [2]. There is a concern that JEV can be introduced into North America given the large population of amplifying hosts—pigs and wild boars, and susceptible *Culex* mosquitoes [3-5]. Japanese encephalitis virus keeps expanding—the 2022 JEV outbreak in Australia with infections in swine herds, zoonotic transmission, and human deaths was caused by genotype IV which was not associated with outbreaks before [6]. West Nile virus is the most common arthropod-borne virus in the US. In 2022, the US Centers for Disease Control and Prevention reported 1,126 cases and 93 deaths. In 2023, there were 2,406 human cases in the US, including 1,599 neuroinvasive diseases. The rising number of human cases caused by mosquito-borne flaviviruses shows the lack or inefficiency of environmental controls. There are no approved human vaccines for some flaviviruses (i.e., Zika, WNV). Also, there are no licensed antivirals against flaviviruses because of a knowledge gap in cellular pathways controlling infections, including the knowledge gap in interactions of viral RNA with cellular proteins.

High-throughput methods enable global analysis of viral RNA–cellular protein interactions. One of the most recent advances in analysis of viral RNA–cellular protein interactions is the Comprehensive Identification of RNA-binding Proteins by Mass Spectrometry (ChIRP-MS) [7],

where interactions between cellular proteins and genomic RNA of several viruses were profiled

that advanced the fundamental knowledge of RNA viruses and informed novel antivirals [8-11].

To our knowledge, all these ChIRP-MS studies were done in wild-type cell lines. And comparative

ChIRP-MS studies on viral RNA–cellular protein interactions in wild-type and knockout (KO) cell

lines are not reported.

The zinc finger CCCH-type antiviral protein 1, also known as ZAP, ZC3HAV1, or PARP13, is a

cellular protein with broad antiviral activity. The protein was first characterized to inhibit murine

leukemia virus [12] and later alphaviruses, filoviruses, influenza virus, porcine reproductive and

respiratory syndrome virus, hepatitis B virus, human cytomegalovirus, human T cell leukaemia

virus type 1, and human immunodeficiency virus-1 [13-23]. The previous study in A549 cells

showed JEV sensitivity to ectopic and endogenous ZAP [24]. In the same study, Zika virus was

not sensitive to ectopic ZAP; the sensitivity of Zika virus to endogenous ZAP was not tested [24].

Another study using ZAP wild-type and ZAP knockout A549 cells showed that wild-type Zika

virus was also not sensitive to antiviral ZAP effects [25]. However, our recent study revealed that

Zika virus was sensitive to endogenous ZAP in VERO cells. Specifically, we observed reduced

viral RNA, infectious titers, and Zika virus NS5 protein expression in wild-type cells compared to

ZAP knockout cells [26]. This discrepancy may be due to the different cell lines used: previous

studies utilized A549 cells derived from human lung cancer tissue [24], while we used VERO cells

from a healthy monkey. Antiviral signaling for many cellular proteins can be highly cell-specific

[27]. Another factor is the species difference: the previous study used a human cell line, and we

used an African green monkey cell line, a possible natural reservoir host of Zika virus [28].

Species-specific ZAP effects are documented [29,30], but comparative studies on ZAP antiviral

activity between primates are lacking.

ZAP binds viral RNA and evokes antiviral activity by mediating viral RNA degradation and

translational inhibition [31]. It also interacts with various cellular proteins that may act as co-

factors, enhancing its antiviral effects [32]. Furthermore, ZAP can augment other antiviral systems

[14,26]. To better understand ZAP–viral RNA–cellular protein interactions, here we used Zika

virus infection in wild-type and ZAP knockout VERO cells as a model. Specifically, we used

ChIRP-MS in mock-infected and Zika-infected wild-type and ZAP knockout cells to characterize

"ZAP-independent" and "ZAP-dependent" cellular protein interactomes associated with flavivirus

RNA. Our findings suggest that ZAP influences cellular proteins associated with Zika virus RNA.

RESULTS

Endogenous ZAP affects flavivirus infection phenotypes in VERO cells

While Zika virus was designated as ZAP-resistant in A549 cells [24,25], in our recent study, we

showed that Zika virus is sensitive to endogenous ZAP in VERO cells with reduced levels of viral

RNA, infectious titers, and NS5 protein expression [26]. Previously we used the multiplicity of

infection (MOI) of 1 for comparative studies in VERO wild-type (VERO-ZAP-WT) and knock-

out (VERO-ZAP-KO) cell lines [26]. Here to further confirm antiviral ZAP effects against Zika

virus we conducted comparative studies in the same cells with low MOI 0.01. We also included

into the comparative study JEV previously shown to be sensitive to endogenous and ectopically

overexpressed ZAP, and WNV with unknown sensitivity to ZAP in VERO cells.

For all flaviviruses, we observed a significant ($p < 0.0001$) reduction in E protein expression in

VERO-ZAP-WT compared to VERO-ZAP-KO cells (**Figs 1A**, **B**, **E**, **F**, **I**, **J**, and **Figs S1, S2, S3**).

All three flaviviruses also showed a considerable reduction of NS5 protein expression in VERO-

ZAP-WT compared to VERO-ZAP-KO cells (**Figs 1D**, **H**, **L**). West Nile virus showed comparable

intracellular viral RNA loads ($p = 0.1875$) in both VERO-ZAP-WT and VERO-ZAP-KO cells

(**Fig 1K**). Consistent with the reduction of E and NS5 protein expression, Zika virus and JEV had

significantly higher intracellular RNA loads in VERO-ZAP-KO cells than in VERO-ZAP-WT

cells ($p = 0.0012$ and 0.0007; **Figs 1C, G**).

Altogether, we confirmed ZAP antiviral effects against JEV and Zika virus, and demonstrated, for

the first time to our knowledge, the sensitivity of WNV to ZAP in VERO cells. Different infection

phenotypes in VERO-ZAP-KO than in VERO-ZAP-WT cells suggested ZAP effects mediated via

viral RNA binding activity which may involve interactions with other cellular proteins. This

motivated us to conduct a ChIRP-MS study to characterize "ZAP-independent" and "ZAP-

dependent" cellular protein interactomes associated with Zika virus RNA.

ChIRP-MS uncovers ZAP-dependent Zika virus RNA interactome

To define the ZAP-depended host protein interactome associated with Zika genomic RNA, we

used the RNA-directed proteomic discovery method ChIRP-MS [7-11] in VERO-ZAP-WT and

VERO-ZAP-KO cell lines. We crosslinked mock-infected and virus-infected cell lines with

formaldehyde to preserve viral RNA–protein complexes and applied biotinylated oligonucleotides

(**Table S1A**) tiling the entire Zika virus RNA to enrich viral RNA–host protein complexes (**Fig**

2A).

For the Zika virus comparative study in VERO-ZAP-WT and VERO-ZAP-KO cells, we used

equal MOIs for inoculation to identify ZAP effects on infection phenotypes (**Fig 1**). However, the

different infection phenotypes in VERO-ZAP-WT and VERO-ZAP-KO cells (**Fig 1**) pose a

challenge for ChIRP-MS study where it is essential to induce equal Zika virus RNA loads in both

cell lines for an accurate comparison of ZAP-dependent and ZAP-independent interactomes. Thus,

before comparing viral RNA–host protein interactions, we tested different Zika MOIs for

inoculation of ZAP-WT and ZAP-KO cells to ensure similar viral RNA loads at the time of

formaldehyde fixation and accurate comparative ChIRP-MS. For this, we incrementally increased

the MOI for VERO-ZAP-WT cells, as Zika virus caused a more aggressive infection in VERO-

ZAP-KO cells (**Fig 1**). The multiplicity of infection 10 for VERO-ZAP-WT cells and MOI 2 for

VERO-ZAP-KO cells evoked similar Zika virus loads. To exclude the effects of differential uptake

of the stimulus during MOI 10 inoculation of VERO-ZAP-WT cells, during VERO-ZAP-KO MOI

2 inoculation we added heat-inactivated Zika virus equivalent of MOI 8. After extensive washing

and 72 h incubation, the same Zika antigen loads in VERO-ZAP-WT and VERO-ZAP-KO cells

were confirmed with viral E protein staining (**Fig 2B**). The same Zika RNA loads in VERO-ZAP-

WT and VERO-ZAP-KO cells were also confirmed using Zika-specific RT-qPCR and next-

generation-sequencing (NGS) in sonicated cellular lysates (**input**) and immunoprecipitated viral

RNA-protein complexes (**enriched**) (**Figs 2C, D; Fig S4; Supplemental Dataset 1**). High RT-

qPCR Zika loads and nearly entire Zika genomic coverage with high NGS depth (**Figs 2C, D; Fig**

S4) confirms that the ChIRP method efficiently recovered the same high loads of viral RNA in

both VERO-ZAP-WT and VERO-ZAP-KO cells. Also, as expected, viral RNA loads were

consistently and considerably (around 10^1 difference) higher in enriched than in input samples in

RT-qPCR and NGS assays (**Figs 2C, D; Fig S4**). Altogether, we confirmed normalized viral loads

and comparable enrichment of viral RNA during ChIRP in VERO-ZAP-WT and VERO-ZAP-KO

cells, permitting quantitative comparison of proteins associated with viral RNA between wild-type

and ZAP-KO cells.

Next, we used the Mass Spectrometry Interaction STatistics (MiST) to analyze raw ChIRP-MS

data (**Supplemental Dataset 2**) previously applied in ChIRP-MS studies [11,33,34]. We employed

MiST with default parameters and used the Singleton Filtering option to exclude proteins with

spectral counts in only one biological replicate, quantifying proteins with a MiST score of 0.75 or

above [11,33,34]. Additionally, we excluded proteins that had at least one spectral count in any

biological replicate of mock-infected wild-type or ZAP-KO cells [11,32]. We applied three

analytical strategies to analyze ChIRP-MS data (**Table S1**):

For the first analytical strategy, using the raw ChIRP-MS data with a total of 2,269 proteins (**Table**

S1B), we identified proteins specifically associated with Zika virus RNA in VERO-ZAP-WT cells.

We defined the resultant list of enriched proteins as the "extended" Zika virus RNA interactome

in VERO-ZAP-WT cells. This extended interactome contains 383 proteins (**Table S1C**). We

named this interactome "extended" because additional control criteria were applied to narrow

down and enrich the "ZAP-dependent" Zika virus RNA interactome (see below).

ChIRP-MS is a rather new technique in molecular biology; the first time it was described for

systemic identification of cellular proteins interacting with cellular mRNA in 2015 [7]. From 2019,

several virology groups have applied ChIRP-MS to characterize interactions between cellular

proteins and genomic RNA of severe acute respiratory syndrome coronavirus 2, Ebola virus,

dengue virus, and Zika virus in wild-type ZAP-positive cells [8-11]. Thus, we compared our

extended Zika virus RNA interactome in VERO-ZAP-WT cells with the Zika interactome in Huh

cells from a previous publication [10]. A similar number of proteins was reported here—383, and

previously—395. The comparison also showed a good reproducibility of 25.4 % between two

protein sets (**Table S1D**). We consider 25.4% a good reproducibility because studies were done in

cells of different species—nonhuman primates (VERO) and humans (Huh), with different MOIs

and sampling time points.

The specificity of our ChIRP-MS is also confirmed by physical associations between Zika virus

RNA and viral prM, C, E, NS1, NS2A, NS2B, NS3, and NS5 proteins in only infected cells, while

all mock-infected replicates were negative (**Table S1E**). The enrichment of viral proteins provides

evidence that ChIRP-MS covers interactions across the entire length of viral RNA [8]. Analysis of

the MiST abundance score and absolute spectral counts showed that the viral NS3 and NS5

proteins were most strongly recovered (**Table S1E**; NS3 MiST abundance score 0.167, NS5 MiST

abundance score 0.304; NS3 mean spectral counts 39, NS5 mean spectral counts 102), which is

consistent with previous ChIRP-MS Zika virus study where NS3 and NS5 were also most abundant

[10]; and with direct binding function of flavivirus NS3—RNA helicase, and NS5—RNA-

dependent RNA polymerase.

Analyzes of top interacting cellular proteins with the highest spectral counts and GO enrichment

analysis also suggested the specificity of ChIRP-MS. All top 15 interacting proteins (except

NCOA5) with the highest spectral counts (**Fig 3A**) are known factors of RNA biology, including

RNA binding, RNA splicing, and RNA helicase activities (**Table S1C**). Gene Ontology

enrichment analysis also showed that all seven enriched pathways with at least two-fold

enrichment represent nucleic acid/RNA binding and RNA biology processes (**Fig 3D**).

For the second analytical strategy, we identified proteins specifically interacting with Zika virus

RNA in VERO-ZAP-KO cells. For specificity, we applied the same strategy as above: We selected

the Singleton Filtering MiST option to exclude proteins with spectral counts in only one biological

replicate and quantify proteins with the MiST score of 0.75 or above [11,33,34]. We also excluded

all proteins with a single spectral count in at least one of three biological replicates in mock-

infected wild-type or ZAP-KO cells. We defined the resultant list of enriched proteins as a "ZAP-

independent" Zika virus RNA interactome. We defined this interactome as ZAP-independent

because associated cellular proteins were discovered in VERO-ZAP-KO cells showing the ZAP-

independent nature of interactions. The ZAP-independent interactome contains 116 proteins

(**Table S1F**). As expected, most, 13 out of 15 top cellular interacting proteins with the highest

spectral counts are known factors in RNA biology (**Fig 3B**; **Table S1F**). Zika virus proteins were

identified in only infected VERO-ZAP-KO cells (**Table S1G**).

Finally, to discover the "ZAP-dependent" Zika RNA interactome in VERO-ZAP-WT cells, in

addition to the above specificity exclusion criteria in MiST settings and mock-infected cells, we

excluded proteins that had at least one spectral count in at least one of the three biological replicates

in VERO-ZAP-KO cells infected with Zika virus. The ZAP-dependent interactome contains 209

proteins (**Table S1H**). The ZAP-dependent Zika RNA interactome has more proteins than ZAP-

independent—209 versus 116 proteins. The difference in 93 proteins between interactomes in

ZAP-WT and ZAP-KO cells is rational because in the previous study a tandem mass spectrometry

showed that 114 cellular proteins interact with the overexpressed immunoprecipitated ZAP large

isoform in uninfected cells [32]. Other large-scale interactome studies in uninfected cells have

identified more than 250 potential cellular proteins that may potentially interact with ZAP [32,35-

38].

As expected, most, 12 out of 15 top interacting proteins with the highest spectral counts in the

ZAP-dependent interactome are known factors in RNA biology (**Fig 3C**; **Table S1H**).

Comparative GO enrichment analysis between ZAP-independent and ZAP-dependent

interactomes showed only one enriched pathway related to RNA biology in ZAP-KO cells and six

enriched RNA biology pathways in ZAP-WT cells, including "helicase activity" with the highest

fold enrichment (**Figs 3E, F**). Accordingly, among the top 15 proteins in the ZAP-dependent

interactome four proteins were RNA helicases (**Table S1H**). In total, 11 RNA helicases were

enriched in the ZAP-dependent interactome—DDX42, DDX56, DDX27, DDX50, DDX52,

DDX23, DDX54, DDX18, DHX57, DDX47, and one uncharacterized RNA helicase (**Tables S1H,**

I).

Altogether, using ChIRP-MS and MiST analysis, we characterized the cellular interactome

associated with Zika virus RNA, including Extended, ZAP-independent, and ZAP-dependent

interactomes.

ZAP wild-type and knockout VERO cells express DDX RNA helicases

ZAP binds cellular mRNA and affects gene expression, including antiviral and immune resolution

transcriptional responses [39,40]. Thus, it was unclear whether the enrichment of RNA helicases

in the ChIRP ZAP-dependent Zika interactome (**Tables S1H; Figs 3C, F**) and the depletion of

RNA helicases in the ChIRP ZAP-independent Zika interactome (**Tables S1F; Figs 3B, E**) were

exclusively due to direct ZAP–viral RNA–cellular RNA helicase interactions in ZAP-WT cells

and the lack of such interactions in ZAP-KO cells, or ZAP-mediated effects on cellular RNA

helicase mRNAs also played a role. Therefore, we quantified the protein levels of four selected

helicases (DDX23, DDX27, DDX42, and DDX50) using Western blot in MOCK and infected

ZAP-WT and ZAP-KO cells (the same MOI and sampling time as for the ChIRP-MS experiment).

DDX42 and DDX27 were chosen because they were among the top three enriched helicases (**Table**

S1I). DDX23 and DDX50 are known to have antiviral activity [41,42].

Western blot analysis revealed expression of all four RNA helicases in both VERO-ZAP-KO and

VERO-ZAP-WT cells, under mock condition and during Zika virus infection (**Fig 4A**). The

expression of DDX23 and DDX27 was lower in both MOCK and Zika virus-infected ZAP-KO

cells compared to ZAP-WT cells (DDX23 $p = 0.0374$; $p = 0.0471$; DDX27 $p < 0.0001$; $p = 0.0004$),

although ZAP-KO cells still showed prominent DDX23 and DDX27 expression (**Figs 4A, B**). Zika

virus infection significantly reduced DDX27 expression in both cell lines (ZAP-KO $p=0.415$;

ZAP-WT $p=0.001$) (**Fig 4A, B**). The expression of DDX42 was significantly lower in mock-

infected ZAP-WT than in ZAP-KO cells ($p = 0.0179$). Zika virus infection considerably reduced

DDX42 expression in both cell lines, but the comparative expression in ZAP-KO and ZAP-WT

cells during infection was similar ($p = 0.2139$) (**Figs 4A, B**). The expression of DDX50 was lower

in both MOCK and Zika virus-infected ZAP-KO cells compared to ZAP-WT cells (MOCK $p =$

0.0001; Zika $p < 0.0001$), although ZAP-KO cells still showed prominent DDX50 expression (**Figs**

4A, B). Zika virus infection did not affect DDX50 expression in either cell line (**Fig 4A, B**).

Overall, we confirmed that ZAP-WT and ZAP-KO cells express all four tested RNA helicases—

DDX23, DDX27, DDX42, and DDX50. However, ZAP knockout was associated with reduced

DDX23, DDX27, and DDX50 expression in both MOCK and infection conditions. These reduced

cellular expressions of DDX23, DDX27, and DDX50 suggest that ZAP-mediated effects on

cellular RNA helicase mRNAs may contribute to the depletion of RNA helicases in the ChIRP

ZAP-independent Zika interactome. In contrast, DDX42 expression was even in ZAP-KO and

ZAP-WT cells during Zika virus infection, indicating that direct interactions between ZAP, viral

RNA, and cellular RNA helicases in ZAP-WT cells may play the central role in the enrichment of

RNA helicases in the ChIRP ZAP-dependent Zika interactome.

DISCUSSION

All previous ChIRP-MS studies on a viral RNA-cellular protein interactome were done in wild-

type cell lines [8-11], and comparative ChIRP-MS studies in wild-type and KO cells were not

reported. Here, using ChIRP-MS in ZAP-WT and ZAP-KO cells, we delineated ZAP-independent

and ZAP-dependent cellular protein interactomes associated with Zika virus RNA. We showed

that such experimental approach is feasible by normalizing MOIs and viral loads in ZAP-WT and

ZAP-KO cells. Despite extensive research on ZAP's antiviral activity, to our knowledge, this study

is the first to explore the ZAP-dependent interactome specifically associated with viral RNA.

ZAP requires RNA helicases as co-factors: ZAP's N-terminus interacts with the N- and C-terminal

domains of DDX17 that promotes ZAP-mediated degradation of murine leukemia reporter virus

[43]. However, our ChIRP-MS Zika data do not contain p72 DEAD-box RNA helicase (DDX17)

(**Table S1B**). DHX30 interacts with ZAP, and the knockdown of DHX30 reduces ZAP's antiviral

activity against murine leukemia reporter virus [44]. Accordingly, we identified DHX30 in ChIRP-

MS data (**Table S1B**); however, it was excluded from further interactome-specific analysis with

our rigorous specificity cutoff. Interestingly, we found that 11 RNA helicases were enriched in the

ZAP-dependent interactome—DDX42, DDX56, DDX27, DDX50, DDX52, DDX23, DDX54,

DDX18, DHX57, DDX47, and one uncharacterized RNA helicase. In contrast, in the ZAP-

independent interactome, no RNA helicases were enriched. The limitation is that our experimental

design does not allow to identify the specific nature of interactions between Zika virus RNA and

cellular proteins. We do not know yet which cellular proteins interact with only ZAP bound to

viral RNA, which interact with ZAP and viral RNA, and which proteins have strict viral RNA

dependency during interactions with ZAP. ZAP binds to single-stranded viral RNA and potentially

to single overhangs in double-stranded RNA [45,46]; RNA helicases can bind to double-stranded

RNA, single overhangs in double-stranded RNA, and single-stranded RNA; these make

interactions between ZAP, viral RNA, and RNA helicases spatially possible. Additional research

is necessary to determine if the RNA helicases identified in this study function as co-factors for

ZAP in its antiviral activity, specifically ZAP-mediated degradation of viral RNA.

In addition to RNA helicases, ZAP requires other co-factors. It lacks intrinsic RNase activity but

recruits the 5' and 3' RNA degradation machinery [24,47]. The E3 ubiquitin ligase TRIM25 is

important for ZAP activity against alphaviruses by increasing inhibition of viral translation

[48,49]. ZAP also interacts with the cytoplasmic protein KHNYN to inhibit CpG-enriched HIV-1

[50]. Riplet, a protein known to play a central role in activating the retinoic acid-inducible gene I

(RIG-I), has been recently identified as a ZAP co-factor that augments the restriction of HIV-1

[51]. However, the full complexity of cellular proteins essential for ZAP antiviral activity is

unknown. Large-scale interactome studies in non-infected cells have identified more than 250

proteins that may interact with ZAP [32,35-38]. Notably, there were no large-scale ZAP

interactome studies in the context of viral infection [35]. Thus, our ZAP-dependent ChIRP-MS

interactome (**Table S1H**) provides a highly specific list of potential ZAP co-factors, including

eleven RNA helicases for future mechanistic and functional studies.

It is known that DDX RNA helicases not only facilitate viral RNA degradation but also act as viral

RNA sensing proteins contributing to cellular innate immune signaling, type I IFN production, and

antiviral response [52-57]. Also, viruses can abduct cellular RNA helicases to support their

lifecycle and promote infectivity [58,59]. Cellular RNA helicases often interact with microbial

genomes and evoke their properties in the complex with different adaptor proteins [52-54,56,60-

62]. Thus, ZAP may play a dual role in mediating RNA helicase-dependent antiviral and proviral

effects. Before our ChIRP-MS study, such co-factor/adaptor role of ZAP in interactions between

viral RNA and cellular RNA helicases was not considered.

Interestingly, Western blot analysis showed that ZAP expression is associated with higher levels

of at least three RNA helicases—DDX23, DDX27, and DDX50—since their expression was

reduced in both MOCK and infected ZAP-KO cells as compared to ZAP-WT cells (**Fig 4**). Thus,

ZAP may indirectly contribute to antiviral cellular responses by maintaining the expression of

RNA helicases, which are known to have antiviral activity, including DDX23 and DDX50 [41,42].

Another interesting finding is that Zika virus infection considerably reduced the expression of

DDX23, DDX 27, and DDX42 in ZAP-WT cells (**Fig 4**), as well as ZAP (**Fig S3**) under our

experimental conditions (72 h post-infection). These observations may indicate Zika virus

strategies for evading cellular immune responses, warranting further investigation.

The primary limitation of this study is its focus on an associative ChIRP-MS comparison between

ZAP-WT and ZAP-KO cells. While conducting functional studies could provide further insights,

it falls beyond the scope of this work. Nonetheless, our ZAP-dependent interactome offers the

scientific community a valuable resource for future studies on ZAP, its co-factors, and viral RNA

interactions. It would also be interesting to compare ChIRP-MS interactomes across different

ZAP-WT and ZAP-KO cell lines infected with various viruses. Our strict filtering approach to

identify the ZAP-dependent interactome, which excluded proteins from the ZAP-independent

interactome even with a single MS spectral count in ZAP-KO cells, might be seen as too rigorous.

However, it ensures a highly specific list of potential ZAP co-factors. Additionally, we have made

available the raw and extended ZAP interactome databases (**Table S1B, C; Supplemental Dataset**

2), allowing others to apply their own filtering approaches.

CONCLUSIONS

Together, the ZAP-dependent interactome identified with ChIRP-MS provides potential ZAP co-

factors for antiviral activity against Zika virus and possibly other viruses. Identifying the full

spectrum of ZAP co-factors and mechanisms of how they act will be critical to understand the

ZAP antiviral system and may contribute to the development of antivirals.

MATERIALS AND METHODS

Details of ChIRP-MS, cells, viruses, comparative infection studies, RT-qPCR, Western blot, and

statistics are in Supplemental Materials and Methods.

DISCLOSURE STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial

relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

Conceptualization: UK. Investigation: NPKL, AJS, PPS, UK. Data analysis: NPKL, AJS, PPS,

UK. Funding: UK. Resources: UK. Writing—original draft preparation: NPKL, AJS, PPS, UK.

Writing—review and editing: UK, NPKL, PPS.

FUNDING

PPS received a Scholarship from the School of Public Health, University of Saskatchewan. This

work was partially supported by a grant to UK from the Canadian Institutes of Health Research

(CIHR; Project Grant #424307). The funders had no role in study design, data collection and

analysis, decision to publish, or manuscript preparation.

DATA AVAILABILITY

Data available within the article, its supplementary materials, and DRYAD open data publishing

platform which can be accessed via links:

https://datadryad.org/stash/share/tqLeKFRU68c947MAFplLF9S8xrd_JM8IulT5JFSiEio
390

391   and

392   https://datadryad.org/stash/share/GJWy9A9Hofp-9aya9oOLI9RgDsi_qqw6FITwPu4F0Gs
393

REFERENCES

1. Amicizia D, Zangrillo F, Lai PL, et al. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO®). Journal of Preventive Medicine and Hygiene2018. p. E99-E107.

2. Tarantola A, Goutard F, Newton P, et al. Estimating the burden of Japanese encephalitis virus and other encephalitides in countries of the mekong region. In: Gray DJ, editor. PLoS neglected tropical diseases2014. p. e2533.

3. Oliveira ARS, Piaggio J, Cohnstaedt LW, et al. Introduction of the Japanese encephalitis virus (JEV) in the United States – A qualitative risk assessment. Transboundary and Emerging Diseases2019. p. 1558-1574.

4. Huang YJS, Harbin JN, Hettenbach SM, et al. Susceptibility of a North American Culex quinquefasciatus to Japanese Encephalitis Virus. Vector borne and zoonotic diseases (Larchmont, N.Y.): Vector Borne Zoonotic Dis; 2015. p. 709-711.

5. Faizah AN, Kobayashi D, Matsumura R, et al. Blood meal source identification and RNA virome determination in Japanese encephalitis virus vectors collected in Ishikawa Prefecture, Japan, show distinct avian/mammalian host preference. J Med Entomol. 2023 Apr 7.

6. Howard-Jones AR, Pham D, Jeoffreys N, et al. Emerging Genotype IV Japanese Encephalitis Virus Outbreak in New South Wales, Australia. Viruses. 2022 Aug 24;14(9).

7. Chu C, Zhang QC, da Rocha ST, et al. Systematic discovery of Xist RNA binding proteins. Cell. 2015 Apr 9;161(2):404-16.

8. Flynn RA, Belk JA, Qi Y, et al. Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. Cell. 2021 Apr 29;184(9):2394-2411 e16.

9. Labeau A, Fery-Simonian L, Lefevre-Utile A, et al. Characterization and functional interrogation of the SARS-CoV-2 RNA interactome. Cell Rep. 2022 Apr 26;39(4):110744.

10. Ooi YS, Majzoub K, Flynn RA, et al. An RNA-centric dissection of host complexes controlling flavivirus infection. Nat Microbiol. 2019 Dec;4(12):2369-2382.

11. Zhang S, Huang W, Ren L, et al. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 2022 Jan;32(1):9-23.

12. Gao G, Guo X, Goff SP. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science (New York, N.Y.): American Association for the Advancement of Science; 2002. p. 1703-6.

13. Bick MJ, Carroll JW, Gao G, et al. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol. 2003 Nov;77(21):11555-62.

14. Nguyen LP, Aldana KS, Yang E, et al. Alphavirus Evasion of Zinc Finger Antiviral Protein (ZAP) Correlates with CpG Suppression in a Specific Viral nsP2 Gene Sequence. Viruses. 2023 Mar 24;15(4).

15. Liu CH, Zhou L, Chen G, et al. Battle between influenza A virus and a newly identified antiviral activity of the PARP-containing ZAPL protein. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14048-53.

16. Mao R, Nie H, Cai D, et al. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013;9(7):e1003494.

17. Muller S, Moller P, Bick MJ, et al. Inhibition of filovirus replication by the zinc finger antiviral protein. J Virol. 2007 Mar;81(5):2391-400.

18. Tang Q, Wang X, Gao G. The Short Form of the Zinc Finger Antiviral Protein Inhibits Influenza A Virus Protein Expression and Is Antagonized by the Virus-Encoded NS1. J Virol. 2017 Jan 15;91(2).

19. Zhu Y, Chen G, Lv F, et al. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively
targeting multiply spliced viral mRNAs for degradation. Proc Natl Acad Sci U S A. 2011 Sep
20;108(38):15834-9.
20. Takata MA, Goncalves-Carneiro D, Zang TM, et al. CG dinucleotide suppression enables antiviral
defence targeting non-self RNA. Nature. 2017 Oct 5;550(7674):124-127.
21. Miyazato P, Matsuo M, Tan BJY, et al. HTLV-1 contains a high CG dinucleotide content and is
susceptible to the host antiviral protein ZAP. Retrovirology. 2019 Dec 16;16(1):38.
22. Gonzalez-Perez AC, Stempel M, Wyler E, et al. The Zinc Finger Antiviral Protein ZAP Restricts
Human Cytomegalovirus and Selectively Binds and Destabilizes Viral UL4/UL5 Transcripts. mBio.
2021 May 4;12(3).
23. Zhao Y, Song Z, Bai J, et al. ZAP, a CCCH-Type Zinc Finger Protein, Inhibits Porcine Reproductive
and Respiratory Syndrome Virus Replication and Interacts with Viral Nsp9. J Virol. 2019 May
15;93(10).
24. Chiu HP, Chiu H, Yang CF, et al. Inhibition of Japanese encephalitis virus infection by the host
zinc-finger antiviral protein. PLoS Pathogens: Public Library of Science; 2018.
25. Fros JJ, Visser I, Tang B, et al. The dinucleotide composition of the Zika virus genome is shaped
by conflicting evolutionary pressures in mammalian hosts and mosquito vectors. PLoS Biol. 2021
Apr;19(4):e3001201.
26. Nguyen Phuong Khanh Le PPS, Ahmad Jawad Sabir, Ivan Trus, Uladzimir Karniychuk. Endogenous
ZAP is associated with altered global cellular gene expression during Zika virus infection. bioRxiv.
2024. https://doi.org/10.1101/2024.05.23.595518
27. Pallett MA, Lu Y, Smith GL. DDX50 Is a Viral Restriction Factor That Enhances IRF3 Activation.
Viruses. 2022 Feb 3;14(2).
28. Buechler CR, Bailey AL, Weiler AM, et al. Seroprevalence of Zika Virus in Wild African Green
Monkeys and Baboons. mSphere. 2017 Mar-Apr;2(2).
29. Kerns JA, Emerman M, Malik HS. Positive selection and increased antiviral activity associated
with the PARP-containing isoform of human zinc-finger antiviral protein. PLoS Genet. 2008
Jan;4(1):e21.
30. Goncalves-Carneiro D, Takata MA, Ong H, et al. Origin and evolution of the zinc finger antiviral
protein. PLoS Pathog. 2021 Apr;17(4):e1009545.
31. Li MMH, Aguilar EG, Michailidis E, et al. Characterization of Novel Splice Variants of Zinc Finger
Antiviral Protein (ZAP). J Virol. 2019 Sep 15;93(18).
32. Goodier JL, Pereira GC, Cheung LE, et al. The Broad-Spectrum Antiviral Protein ZAP Restricts
Human Retrotransposition. PLOS Genetics: Public Library of Science; 2015. p. e1005252.
33. Verschueren E, Von Dollen J, Cimermancic P, et al. Scoring Large-Scale Affinity Purification Mass
Spectrometry Datasets with MiST. Curr Protoc Bioinformatics. 2015 Mar 9;49:8 19 1-8 19 16.
34. Jager S, Cimermancic P, Gulbahce N, et al. Global landscape of HIV-human protein complexes.
Nature. 2011 Dec 21;481(7381):365-70.
35. Ficarelli M, Neil SJD, Swanson CM. Targeted Restriction of Viral Gene Expression and Replication
by the ZAP Antiviral System. Annu Rev Virol. 2021 Sep 29;8(1):265-283.
36. Caudron-Herger M, Rusin SF, Adamo ME, et al. R-DeeP: Proteome-wide and Quantitative
Identification of RNA-Dependent Proteins by Density Gradient Ultracentrifugation. Mol Cell.
2019 Jul 11;75(1):184-199 e10.
37. Huttlin EL, Bruckner RJ, Paulo JA, et al. Architecture of the human interactome defines protein
communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
38. Youn JY, Dunham WH, Hong SJ, et al. High-Density Proximity Mapping Reveals the Subcellular
Organization of mRNA-Associated Granules and Bodies. Mol Cell. 2018 Feb 1;69(3):517-532 e11.

39.   Todorova T, Bock FJ, Chang P. PARP13 regulates cellular mRNA post-transcriptionally and
510   functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript. Nat Commun. 2014 Nov
511   10;5:5362.
512   40.   Schwerk J, Soveg FW, Ryan AP, et al. RNA-binding protein isoforms ZAP-S and ZAP-L have distinct
513   antiviral and immune resolution functions. Nat Immunol. 2019 Dec;20(12):1610-1620.
514   41.   Abdullah SW, Han S, Wu J, et al. The DDX23 Negatively Regulates Translation and Replication of
515   Foot-and-Mouth Disease Virus and Is Degraded by 3C Proteinase. Viruses. 2020 Nov 25;12(12).
516   42.   Han P, Ye W, Lv X, et al. DDX50 inhibits the replication of dengue virus 2 by upregulating IFN-
517   beta production. Arch Virol. 2017 Jun;162(6):1487-1494.
518   43.   Chen G, Guo X, Lv F, et al. p72 DEAD box RNA helicase is required for optimal function of the
519   zinc-finger antiviral protein. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4352-7.
520   44.   Ye P, Liu S, Zhu Y, et al. DEXH-Box protein DHX30 is required for optimal function of the zinc-
521   finger antiviral protein. Protein Cell. 2010 Oct;1(10):956-64.
522   45.   Xu S, Ci Y, Wang L, et al. Zika virus NS3 is a canonical RNA helicase stimulated by NS5 RNA
523   polymerase. Nucleic Acids Res. 2019 Sep 19;47(16):8693-8707.
524   46.   Luo X, Wang X, Gao Y, et al. Molecular Mechanism of RNA Recognition by Zinc-Finger Antiviral
525   Protein. Cell Rep. 2020 Jan 7;30(1):46-52 e4.
526   47.   Zhu Y, Gao G. ZAP-mediated mRNA degradation. RNA Biol. 2008 Apr-Jun;5(2):65-7.
527   48.   Li MM, Lau Z, Cheung P, et al. TRIM25 Enhances the Antiviral Action of Zinc-Finger Antiviral
528   Protein (ZAP). PLoS Pathog. 2017 Jan;13(1):e1006145.
529   49.   Zheng X, Wang X, Tu F, et al. TRIM25 Is Required for the Antiviral Activity of Zinc Finger Antiviral
530   Protein. Journal of virology: J Virol; 2017.
531   50.   Ficarelli M, Wilson H, Pedro Galão R, et al. KHNYN is essential for the zinc finger antiviral protein
532   (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. eLife2019.
533   51.   Buckmaster MV, Goff SP. Riplet Binds the Zinc Finger Antiviral Protein (ZAP) and Augments ZAP-
534   Mediated Restriction of HIV-1. Journal of Virology: American Society for Microbiology; 2022.
535   52.   Zhang Z, Kim T, Bao M, et al. DDX1, DDX21, and DHX36 helicases form a complex with the
536   adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity. 2011 Jun 24;34(6):866-78.
537   53.   Kim T, Pazhoor S, Bao M, et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA
538   helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad
539   Sci U S A. 2010 Aug 24;107(34):15181-6.
540   54.   Zhang Z, Yuan B, Lu N, et al. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid
541   dendritic cells. J Immunol. 2011 Nov 1;187(9):4501-8.
542   55.   Pattabhi S, Knoll ML, Gale M, Jr., et al. DHX15 Is a Coreceptor for RLR Signaling That Promotes
543   Antiviral Defense Against RNA Virus Infection. J Interferon Cytokine Res. 2019 Jun;39(6):331-
544   346.
545   56.   Miyashita M, Oshiumi H, Matsumoto M, et al. DDX60, a DEXD/H box helicase, is a novel antiviral
546   factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol. 2011 Sep;31(18):3802-19.
547   57.   Ermler ME, Yerukhim E, Schriewer J, et al. RNA helicase signaling is critical for type i interferon
548   production and protection against Rift Valley fever virus during mucosal challenge. J Virol. 2013
549   May;87(9):4846-60.
550   58.   Steimer L, Klostermeier D. RNA helicases in infection and disease. RNA Biol. 2012 Jun;9(6):751-
551   71.
552   59.   Wu CY, Nagy PD. Role reversal of functional identity in host factors: Dissecting features affecting
553   pro-viral versus antiviral functions of cellular DEAD-box helicases in tombusvirus replication.
554   PLoS Pathog. 2020 Oct;16(10):e1008990.
555   60.   Cheng W, Chen G, Jia H, et al. DDX5 RNA Helicases: Emerging Roles in Viral Infection. Int J Mol
556   Sci. 2018 Apr 9;19(4).

557   61.   Mitoma H, Hanabuchi S, Kim T, et al. The DHX33 RNA helicase senses cytosolic RNA and
558   activates the NLRP3 inflammasome. Immunity. 2013 Jul 25;39(1):123-35.
559   62.   Zhang Z, Yuan B, Bao M, et al. The helicase DDX41 senses intracellular DNA mediated by the
560   adaptor STING in dendritic cells. Nat Immunol. 2011 Sep 4;12(10):959-65.

  FIGURE LEGENDS

Fig 1. ZAP affects JEV, Zika, and WNV infection phenotypes. Representative images of cells
positive for JEV (**A**), Zika virus (**E**), and WNV (**I**) E protein (red staining) at 72 h (48 h for WNV),
MOI 0.01. Magnification x200. The experiment was done in 3 biological and 3 technical replicates.
Figures represent the general patterns in all replicates. All 9 replicates for VERO-ZAP-WT and
VERO-ZAP-KO cells are shown in **Fig S1**. The digital quantification of JEV (**B**), Zika (**F**), and
WNV (**J**) positive cells in all 9 replicates from **Fig S1**. *****Unpaired t-test: *P* < 0.05. In mock-infected
cells digital sensitive counting represents the staining background. The fold increase of JEV (**C**),
Zika (**G**), and WNV (**K**) RNA loads in cell lysates collected at 1 h and 72 h (48 h for WNV) after
inoculation. VERO-WT and VERO-ZAP-KO cells were inoculated with MOI 0.01. Virus
inoculums were removed and replaced with media. Cell lysates were collected with a lysis buffer
at 1 h post-inoculation (to normalize for leftover virus inoculum RNA) and at 48-72 h. *****Unpaired
t-test: *P* < 0.05. The experiment was done in 3 biological and 2 technical replicates. (**D**, **H**, **L**)
Reduced flavivirus infection in VERO-ZAP-WT cells at 72 h (48 h for WNV) represented by
western blot for NS5 proteins. Normalized 50 µg of protein was used for all samples. Two
biological replicates for each condition are shown.

Fig 2. ChIRP-MS study design and validation. (A) ChIRP-MS experimental design to compare
viral RNA–host protein interactions in ZAP-positive and ZAP-KO cells. ChIRP-MS was done in
three biological replicates; each biological replicate consisted of lysed cells from four T-175 flasks
for each experimental condition. **(B)** We adapted normalized MOIs to induce similar Zika viral
loads in ZAP-WT and ZAP-KO cells. Red staining represents a similar number of Zika virus E
protein-positive cells in WT and KO cells. Inserts—mock-infected cells. **(C)** The same Zika RNA
loads in ZAP-WT and ZAP-KO cells were also confirmed using RT-qPCR. **Input** - sonicated
cellular lysates. **Enriched** - immunoprecipitated viral RNA-protein complexes bound to MyOne
C1 magnetic beads at the last washing step before protein elution. RNA was extracted from a 40
ul of cell lysate or bead suspension in the washing buffer representing each biological replicate
and subjected to Zika virus-specific RT-qPCR; dots represent ChIRP-MS biological replicates.
(D) The same nearly entire Zika RNA genome coverage and NGS depth in ZAP-WT and ZAP-
KO cells. Representative data from one ChIRP-MS biological replicate for ZAP-WT and ZAP-
KO cells. **Input** and **Enriched** are the same sample types as for RT-qPCR in **C**. Control NGS in
mock-infected cells did not show Zika-specific sequences (**Fig S4**). A red line shows the 10-
nucleotide NGS depth threshold.

Fig 3. Top ChIRP-MS proteins and GO pathways identified in the Extended, ZAP-
independent, and ZAP-dependent Zika virus RNA interactomes. Mean spectral counts are
shown for proteins in (**A**, **B**, **C**). Spectral counts for all three biological replicates are shown in
Tables S1C, F, H. The top proteins with unknown functions in RNA biology are highlighted in
grey. For GO pathways in (**D, E, F**), GO identification numbers and FDR-adjusted *P* values are
shown in parentheses. All GO processes were overrepresented.

Fig 4. The expression of RNA helicases in VERO-ZAP-WT and VERO-ZAP-KO cells. Cells
were mock infected or infected with normalized Zika virus MOIs; MOI 2 or 10 for VERO-ZAP-
KO and VERO-ZAP-WT cells, respectively, as described for ChIRP in supplemental materials
and methods. Cells were sampled at 72 h after mock or virus infection. (**A**) Green bands represent
DDX23 (96 kDa), DDX27 (90 kDa), DDX42 (117-120 kDa), and DDX50 (83 kDa) RNA

helicases. Red bands represent β-actin loading control (42 kDa). Western blot was done in 3
biological replicates for each experimental condition. (**B**) The expression of DDX RNA helicases
was quantified as described in supplemental material and methods.

FIGURES

Fig 1.

676   **Fig 2.**

Extended Zika virus RNA interactome

ZAP-independent Zika virus RNA interactome

ZAP-dependent Zika virus RNA interactome

Fig 3.

Fig 4.

SUPPORTING INFORMATION CAPTIONS

Supplemental Materials and Methods. The file contains experimental details.

Fig S1. Representative images of cells positive for flavivirus E protein (red staining) at 72 h (JEV and Zika virus) and 48 h (WMV). The experiment was done in 3 biological and 3 technical replicates. All replicates are shown. MOI 0.01. The data from these replicate figures were used for digital quantification in **Figs 1B**, **F**, **J**. (**A**) JEV in VERO-ZAP-WT cells. (**B**) JEV in VERO-ZAP-KO cells. (**C**) Zika virus in VERO-ZAP-WT cells. (**D**) Zika virus in VERO-ZAP-KO cells. (**E**) WNV in VERO-ZAP-WT cells. (**F**) WNV in VERO-ZAP-KO cells.

Fig S2. VERO-ZAP-WT and VERO-ZAP-KO cells genotyped with Sanger sequencing as described in Supplemental Materials and Methods. Location of indels on *Chlorocebus sabaeus* genome: -2bp deletion, NW_023666072.1: 4677550-4677551.

Fig S3. ZAP Western blot. (A) ZAP Western blot in VERO-ZAP-KO and VERO-ZAP-WT cells. Cells were mock infected or infected with normalized Zika virus MOIs; MOI 2 or 10 for VERO-ZAP-KO and VERO-ZAP-WT cells, respectively, as described for ChIRP in supplemental materials and methods. Cells were sampled at 72 h after mock or virus infection. Green bands represent ZAP with the manufacturer's predicted size 111 kDa; multiple bands may represent four isoforms described for human ZAP [31] and still not experimentally characterized for monkeys. Red bands represent β-actin loading control, 42 kDa. Western blot was done in 3 biological replicates for each experimental condition. (**B**) The expression of ZAP was quantified as described in supplemental material and methods.

Fig S4. The Zika RNA genome coverage and NGS depth in VERO-ZAP-WT and VERO-ZAP-KO cells. **Input** - sonicated cellular lysates. **Enriched** - immunoprecipitated viral RNA-protein complexes bound to MyOne C1 magnetic beads at the last washing step before protein elution. Control NGS in mock-infected cells did not show Zika-specific sequences. A red line shows the 10-nucleotide NGS depth threshold.

Table S1-ChIRP-MS data. The table contains raw and analyzed ChIRP-MS data. The table can be accessed in the DRYAD open data publishing platform:
https://datadryad.org/stash/share/tqLeKFRU68c947MAFplLF9S8xrd_JM8IulT5JFSiEio

Supplemental Dataset 1. This dataset contains 26 raw fastq files representing paired-end NGS data for **input** and **enriched** samples described in results, in **Figure 2D**, and in **Fig S4**. The dataset also contains the "Zika virus NGS sample IDs" file which provides identifications for raw files and experimental conditions (VERO-ZAP-WT or VERO-ZAP-KO cells; MOCK or Zika virus; input or enriched samples; replicate number). The dataset can be accessed in the DRYAD open data publishing platform:
https://datadryad.org/stash/share/GJWy9A9Hofp-9aya9oOLI9RgDsi_qqw6FITwPu4F0Gs

Supplemental Dataset 2. This dataset contains the folder "RAWfiles" with 12 Mass

spectrometry RAW data files representing three biological replicates for MOCK and Zika virus-

infected VERO-ZAP-WT and VERO-ZAP-KO cells. The folder "MSFragger" contains the

output of FragPipe v18.0 which was used to analyze Mass spectrometry RAW data files as

described in Supplemental Materials and Methods. The folder "MSFragger" contains data for

individual samples, and the "combined_protein.tsv" file (also represented in **Table S1B**), which

was used for the identification of Extended, ZAP-independent, and ZAP-dependent Zika virus

RNA interactomes from ChIRP-MS results as described in Supplemental Materials and Methods.

The "Zika virus ChIRP-MS sample IDs" file provides identifications for Mass spectrometry and

FragPipe raw files and experimental conditions (VERO-ZAP-WT or VERO-ZAP-KO cells;

MOCK or Zika virus; biological replicate number). The dataset can be accessed in the DRYAD

open data publishing platform:

https://datadryad.org/stash/share/GJWy9A9Hofp-9aya9oOLI9RgDsi_qqw6FITwPu4F0Gs

SUPPLEMENTAL MATERIALS AND METHODS

Endogenous ZAP affects Zika virus RNA interactome

Ahmad Jawad Sabir[1,a], Nguyen Phuong Khanh Le[2,a], Prince Pal Singh[2,3,a], Uladzimir

Karniychuk[2,*]

[1]Department of Microbiology and Immunology, University of Illinois, College of Medicine,

Chicago, IL, USA

[2]Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State

University, Columbus, OH, USA

[3]School of Public Health, University of Saskatchewan, Saskatoon, Canada

[a]**:** These authors contributed equally

* Correspondence: Uladzimir Karniychuk
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State
University, Columbus, OH, USA
karniychuk.1@osu.edu
24

SUPPLEMENTAL MATERIALS AND METHODS

Cells

Wild-type and ZAP knockout VERO cells were previously described [1]. Briefly, wild-type

VERO E6 cells (ATCC) (VERO-ZAP-WT) and ZAP knockout (VERO-ZAP-KO) derivatives

were maintained in DMEM (Fisher, MA, USA; #11-965-118) supplemented with 10% heat-

inactivated fetal bovine serum (FBS) (Fisher, MA, USA; #A5256801), 1x Penicillin-

Streptomycin (Fisher, MA, USA; #15140122), and 2.67 mM sodium bicarbonate (Fisher, MA,

USA; # 25080094) at +37°C in a 5% CO_2 humidified incubator. To generate Zinc finger CCCH-

type antiviral protein 1 (ZAP) KO cell line, we used the guide RNA (gRNA)

GTCTCTGGCAGTACTTGCGA which targets the first exon of *Chlorocebus sabaeus* (Gene ID:

103226990) ZC3HAV1 gene, which is required for the expression of all ZAP isoforms. A non-

targeting control gRNA ACGGAGGCTAAGCGTCGCAA was also used. These gRNAs were

transiently transfected into cells using GenCrispr NLS-Cas9-NLS Nuclease (GenScript).

Transfected cells were plated in 96-well plates by limiting dilution to generate isogenic single

clones. The clones were expanded and genotyped with Sanger sequencing; primers (F-

ATCGCTGGGCTGGACTAACG, R-GCAGAGAAGGGAGTGGCTGAA) were used to

identify indels (location of indels on *Chlorocebus sabaeus* genome: -2bp deletion,

NW_023666072.1: 4677550-4677551; **Fig S2**). The knock-out subclone verified by genotyping

was further confirmed by western blot [1] (**Fig S3**). The negative control cells were not isolated

into single clones, but they were validated by Sanger sequencing to confirm there were no indels

(**Fig S2**). Free mycoplasma contamination status in cells was confirmed using the LookOut

Mycoplasma PCR Detection Kit (Millipore Sigma, MA, USA; #MP0035).

Viruses

We used the Asian lineage Zika virus H/PF/2013 strain. Zika virus was synthetically rescued

with reverse genetics in our previous study [2]; H/PF/2013 [GenBank: KJ776791.2] reference

sequence was used to rescue the virus. For JEV (SA14-14-2 strain, GenBank MK585066.1) and

WNV (NY99 strain, GenBank: DQ211652.1), we used the same reverse genetics system [2].

Viruses were propagated in VERO cells in DMEM supplemented with 2% FBS and 1%

penicillin/streptomycin (P/S). Supernatants were centrifuged (12,000 g, 20 min, +4°C),

aliquoted, and frozen (-80°C). Infectious virus titers were quantified using VERO E6 cells with

the endpoint dilution assay, and fifty percent tissue culture infective dose (TCID$_{50}$) endpoint

titers were calculated as previously described [2-5]. Media from virus-negative VERO cells was

processed in the same manner and used in control conditions. Free mycoplasma contamination

status in virus stocks was confirmed using the LookOut Mycoplasma PCR Detection Kit

(Millipore Sigma, MA, USA; #MP0035).

**Comparative infection phenotypes in wild-type and ZAP-KO cells infected with Zika virus,
JEV, and WNV**

We tested alongside JEV, Zika virus, and WNV in VERO-ZAP-WT and VERO-ZAP-KO cells.

Fifty thousand cells per well were seeded into 96-well plates; next day, media was removed, and

monolayers were inoculated with MOIs 0.01 of JEV, Zika, or WNV in 50 µl for 2 h at +37°C

and 5% CO_2. Afterward, the inoculum was removed and replaced with 150 µl DMEM

supplemented with 2% FBS, 1x Penicillin-Streptomycin, and 2.67 mM sodium bicarbonate. At 1

h and 72 h (48 h for WNV), cells in 9 wells representing three biological and three technical

replicates were fixed and stained for flavivirus E protein as we did [2,5-9]. For

immunohistochemistry staining we used 4G2 (ATCC, MA, USA; #HB-112) antibodies (Ab)

against Zika and WNV E protein, and #GTX125867 Ab (GeneTex, CA, USA) against JEV E

protein [2-5]. To quantify and compare immunohistochemistry staining between ZAP-WT and

ZAP-KO conditions, a magnification x200 images were randomly acquired in all replicates with

the same microscopic settings. Afterward each image was procced in ImageJ (NIH, USA) with

Automatic Particle counting (https://imagej.net/imaging/particle-analysis). In addition, cell

lysates from 3 biological and 2 technical replicates were collected at the same time points with

140 µl of PureLink RNA Mini Kit lyses buffer (Invitrogen) for subsequent RNA extraction and

virus-specific RT-qPCR [4,5,8,10]. The difference between ZAP-WT and ZAP-KO conditions

was represented by fold change of viral RNA loads in cell lysates collected at 1 h and 72 h (48 h

for WNV) after inoculation (1 h after inoculation was used to normalize for leftover virus

inoculum RNA).

RNA extraction and virus-specific reverse transcriptase quantitative polymerase chain

reaction assays (RT-qPCR)

To quantify intracellular Zika virus, JEV, and WNV RNA, total RNA was extracted from cell

lysates with PureLink RNA Mini Kit (Invitrogen) according to the manufacturer's instructions.

All RT-qPCR reactions were conducted on the Applied Biosystems QuantStudio 3 real-time

PCR system (Fisher, MA, USA) and analyzed using QuantStudio Design & Analysis Software

v1.5.2.

For Zika virus RNA quantification, we used the previously validated SYBR one-step RT-qPCR

assay [11]. The Luna Universal One-Step RT-qPCR Kit (NEB, MA, USA; # E3005L) reaction

mixture (20 µL) consisted of 10 µL Luna Universal One-Step Reaction Mix, 1 µL Luna

WarmStart RT Enzyme Mix, 1 µL (10 µM) of forward (ZIKV-F-SYBR: 5′-

AGGATCATAGGTGATGAAGAAAAGT-3′) and reverse (ZIKV−R-SYBR: 5′-

CCTGACAACACTAAGATTGGTGC-3′) primers, 3.4 µL nuclease-free water and 4 µL of RNA

template. The reverse transcription and enzyme activation steps of 10 min at 55˚C and 1 min at

95˚C were followed by 40 amplification cycles (10 s at 95˚C and 60 s at 60˚C). A standard curve

was generated and used to quantify Zika RNA loads as we described [1,2,4].

For JEV (F: 5′-GCCACCCAGGAGGTCCTT-3′; R: 5′-CCCCAAAACCGCAGGAAT-3′; Probe:

56-FAM-CAAGAGGTG/ZEN/GACGGCC-3IABkFQ) and WNV (F: 5′-

AGTAGTTCGCCTGTGTGAGC-3′; R: 5′-GCCCTCCTGGTTTCTTAGA-3′; Probe: 5'-FAM-

AATCCTCACAAACACTACTAAGTTTGTCA-TAMRA-3'), we used the previously validated

probe-based one-step RT-qPCR assays [12,13]. The Luna Universal Probe One-Step RT-qPCR

Kit reaction mixture (20 µL) consisted of 10 µL Luna Universal Probe One-Step Reaction Mix, 1

µL Luna WarmStart RT Enzyme Mix, 1 µL (10 µM) of forward and reverse primers, 0.5 µL of

the probe, 2.5 µL nuclease-free water and 4 µL of RNA template. The reverse transcription and

enzyme activation steps of 10 min at 55˚C and 1 min at 95˚C were followed by 40 amplification

cycles (10 s at 95˚C and 30 s at 60˚C). A standard curve was used to quantify viral RNA loads as

we described [1,2,4,6].

PCR values were corrected for volumes (140 µl of cell lyses buffer) and upon logarithmical

transformation expressed as virus RNA genome copies per mL. Strict precautions were taken to

prevent PCR contamination. All master mix preparations were done in the dedicated PCR

cabinet. Aerosol-resistant filter pipette tips and disposable gloves were used. Kit reagent controls

were included in every RNA extraction and PCR run.

Western blot

Cells in T-75 or T-175 flasks were washed, pelletized, and lysed in 150 or 300 μL of RIPA

buffer (Fisher, MA, USA; # PI89900) supplemented with 1× Halt protease inhibitor cocktail

(Fisher, MA, USA; # PI87786) and 1× EDTA (Fisher, MA, USA; #BP2482100). After 10

minutes of incubation on wet ice, the suspension was gently vortexed and centrifuged (12,000g,

10 min, +4 °C). Supernatants were aliquoted in prechilled low protein binding tubes and stored at

−80°C. After quantifying protein concentration with the Pierce BCA Protein Assay Kit (Fisher,

MA, USA; # PI23225), 50 μg of protein extract was mixed with 4x reducing Laemmli SDS

sample buffer (Fisher, MA, USA; # AAJ60015AC), boiled at 95ºC for 10 min, and resolved

using a 10% Mini-PROTEAN TGX precast protein gels (Bio-Rad, CA, USA; #4561036)

running in 1X Tris/Glycine/SDS running buffer (Bio-Rad, CA, USA; # 1610772) at a constant

current of 125V for 70 min. Proteins were transferred to methanol-activated 0.45 μm Immun-

Blot Low Fluorescence polyvinylidene fluoride (PVDF) (Bio-Rad, CA, USA; #1620260)

membranes using Trans-Blot Turbo RTA Mini 0.45μm LF PVDF Transfer Kit (Bio-Rad, CA,

USA; #1704274). Afterward, PVDF membranes were blocked with 1X VWR Life Science

Rapidblock Blocking Solution (VWR, GA, USA; #97064-124) for 1 h at room temperature. The

blocked membranes were incubated with primary antibody diluted in blocking solution overnight

at +4°C. Membranes were washed four times with TBST (1x Bio-Rad Tris Buffered Saline

containing 0.1% of Fisher Tween-20). After that, membranes were incubated with secondary

antibody along with hFAB™ Rhodamine Anti-Actin Primary Antibody (Recombinant human β-

actin) diluted in Blocking Solution for 1 h at room temperature, and washed four times with

TBST. Fluorescent blots were imaged on the ChemiDoc MP Imaging system (Bio-Rad, CA,

USA) using an appropriate detection channel with Image Lab Touch Software (Bio-Rad, CA,

USA).

We used antibodies (Abs): Rabbit anti-ZAP IgG Abs (1:1,000 dilution; ANTI-ZC3HAV1

#HPA059096-100UL, Millipore Sigma, MA, USA), Rabbit anti-DDX23 IgG Abs (1:1,000

dilution; #ab70461, Abcam, MA, USA), Rabbit anti-DDX27 IgG Abs (1:1,000 dilution;

#ab177938, Abcam, MA, USA), Rabbit anti-DDX42 IgG Abs (1:2,000 dilution; Fisher, MA, USA;

#A303-353A), Rabbit anti-DDX50 IgG Abs (1:1,000 dilution; #10358-1-AP; ProteinTech, IL,

USA), Rabbit anti-Zika virus NS5 IgG Abs (1:1,000 dilution; #GTX133312; GeneTex, CA, USA),

Rabbit anti-West Nile virus NS5 IgG Abs (1:1,500, #GTX131961; GeneTex, CA, USA), Rabbit

anti-Japanese Encephalitis virus NS5 Abs (1:1,500, #GTX131359; GeneTex, CA, USA), hFAB™

Rhodamine Anti-Actin Primary Abs (1:3,000; #12004164; Bio-Rad, CA, USA), and IRDye®

680RD Goat anti-Rabbit IgG secondary Abs (1:10,000; #926-68071; LI-COR, NE, USA).

Image Lab Software Version 6.1 (Bio-Rad, CA, USA) was used for Western blots densitometry

analysis according to the user guide instructions. Briefly, the "Lanes and Bands" option was used

to select the specific lanes and bands of the corresponding DDX RNA helicase, ZAP, and β-actin

lanes and bands. The "Lane Profile" option was used to subtract the background. In the "Analysis

Table," the background-adjusted (Adj. Volume) intensities of each DDX RNA helicase and ZAP

bands were normalized by the background-adjusted β-actin intensities. Subsequently, the DDX

RNA helicase (or ZAP)/β-actin ratios were used to analyze data for each experimental condition.

Comprehensive Identification of RNA binding Proteins by Mass Spectrometry (ChIRP-MS)

We performed ChIRP-MS as described before [14-17]. Biotinylated DNA probes (**Table S2A**) covering the whole Zika virus genome were designed using the online tool (https://www.biosearchtech.com/chirp-designer). To have an even coverage of the whole genome, 50 probes were designed by dividing the whole Zika reference sequence H/PF/2013 [GenBank: KJ776791.2] into two segments (1-5400 and 5401-10807), with a repeat masking setting of 3 and spacing length of 80 (1 oligo around every 200 bp). Oligos were synthesized with 3' biotin-TEG modification, final yield of 2 OD, and HPLC purification at Bio Basic Inc, Canada. Fifty individual oligos were resuspended at 100 µM and mixed at equal volumes to prepare the probe pool.

For Zika virus infection, VERO-ZAP-WT and VERO-ZAP-KO cells were seeded at 10^7 cells per T-175 flask (4 flasks per experimental condition x 3 biological replicates) and were grown in DMEM supplemented with 10% FBS. The next day, the media was removed, and cell monolayers were washed with 1× PBS and inoculated with Zika virus at MOI 10 for VERO-ZAP-WT cells and MOI 2 for VERO-ZAP-KO cells; these MOIs were adapted to provide the same Zika virus loads. For this, we incrementally increased the MOI for VERO-ZAP-WT cells, as Zika virus caused a more aggressive infection in VERO-ZAP-KO cells (**Figs 1E-H**). To exclude the effects of differential uptake of the stimulus with MOI 10 in VERO-ZAP-WT cells, during VERO-ZAP-KO MOI 2 Zika virus inoculation we added heat-inactivated virus equivalent of MOI 8. Control cells were mock-treated with supernatant from virus-free control cells. Flasks were incubated at 37°C for 2 h and gently shaken every 10 minutes. The inoculum from flasks

was removed, and monolayers were extensively washed with 1× PBS twice and 25 mL of

DMEM supplemented with 2% FBS was added to each flask.

After 72 h, for cell harvesting and chemical crosslinking, media was removed, cell monolayers

were rinsed with 1× PBS, trypsinized, washed, and cells from four T-175 flasks representing one

biological replicate were pooled for each experimental condition. Cells were cross-linked in 37

mL of 3% methanol free-formaldehyde (Fisher, MA, USA; #PI28908) diluted in 1× PBS and

incubated for 30 min at room temperature on a rotator. Afterwards, formaldehyde was quenched

with 3.7 mL of 1.25 M glycine (Fisher, MA, USA; #AAA1381636) with final concentration 125

mM and pelleted (2,000g, 5 min, +4°C). Cell pellets were washed, resuspended in 2.5ml of 1×

PBS, transferred to pre-weighed microcentrifuge tubes, and centrifuged (10,000g, 2 min, +4°C).

PBS was aspirated, tubes were placed on ice and weighted on an analytical scale to determine the

final pellet weight, snap frozen in liquid nitrogen, and stored at -80°C. Around 300 mg of cells

was obtained from four combined T-175 flasks (4 flasks per experimental condition x 3

biological replicates).

For cell lysis and sonication, cell pellets were thawed at RT, resuspended in the ChIRP lysis

buffer (50 mM Tris-HCl, pH 7.0, # BP1756500; 10 mM EDTA, #AAJ62786AK; 1% SDS, #

BP2436-200; all reagent are from Fisher, MA, USA) supplemented just before use with PMSF

(100 mM; #PI36978, Fisher, MA, USA; 10 µl per 1 ml of ChIRP lysis buffer), SUPERaseIn (20

U/ µl; #AM2694, Fisher, MA, USA; 10 ul per 1 ml of ChIRP lysis buffer), and protease inhibitor

(100x; #P178410, Fisher, MA, USA; 10 ul per 1 ml of ChIRP lysis buffer) to finally have 300

mg of cell pellet per 4 ml of the complete lysis buffer. The lysate from each sample were

aliquoted in 2 ml and sonicated using Sonics Ultrasonic Processor VCX750 with 3 mm microtip

at 20% amplitude with 15 seconds On, 45 seconds Off pulse intervals for 1 h (1 h for total 15 +

45 seconds On and Off intervals) in 15 mL MI Bioruptor Plus TPX Tubes (#C30010009;

HOLOGIC Diagenode, NJ, USA). The sonicated lysates were snap frozen in liquid nitrogen and

stored at -80°C until further use. Aliquots of sonicated lysates (40 µL) were used to extract

RNA/DNA with the Invitrogen PureLink RNA Mini Kit (#12-183-018A; Fisher, MA, USA)

according to manufacturer's instructions, and the efficiency of sonication was confirmed by

running extracts from all samples on 1% agarose gels. The average DNA/RNA length was

around 500 nucleotides in all samples. The RNA from these samples were also used for Zika-

specific RT-qPCR and Next Generation Sequencing (NGS) to analyze the entire Zika virus RNA

loads, genome coverage and NGS depth (see below and results).

For hybridization, sonicated lysates were thawed on ice and pre-cleaned by adding 30 µL washed

Invitrogen Dynabeads MyOne Streptavidin C1 (# 65001; Fisher, MA, USA) per 1 mL of lysate

and rotating at 37°C for 30 min in a hybridization oven. Beads were removed twice from lysates

using a magnetic stand; for this and all subsequent magnetic stand steps > 2 min magnetization

was applied before removing the supernatant. Next, for every 1 mL of pre-cleaned sonicated

lysate, 2 mL of ChIRP hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris-HCl pH 7.0,

1 mM EDTA, 15% formamide supplemented with PMSF, SUPERaseIn, and protease inhibitor as

described above for lysis buffer) and 2.5 µL of the 100 µM ChIRP probe pool were added. In our

experiments, the total volume of pre-cleaned sonicated lysate and ChIRP hybridization buffer

was 12 ml per sample; for efficient hybridization, we distributed each sample in 6 ml aliquots

and rotated in the hybridization over for 16 h at 37°C.

For enrichment of hybridized Zika virus RNA and associated proteins, per 1 mL of the initial

sample, 250 μL of washed (washed 3 times in un-supplemented lysis buffer) Dynabeads MyOne

Streptavidin C1 was added in each sample (in our study, 1 ml of beads was added per initial 4 ml

lysis buffer sample), and rotated in the hybridization oven for 45 min at 37°C. Two 15 ml tubes

representing one sample were placed on the magnetic stand, supernatants were removed, and

beads were combined in 1 ml of ChIRP wash buffer (2x SSC, #AAJ60561AP, Fisher, MA, USA;

0.5% SDS supplemented with 1 mM PMSF just before use) in 1.5 ml low-binding Eppendorf

tube. Afterward, beads were washed 5 times in 1 ml of the ChIRP wash buffer by rotating at

37°C for 5 min in the hybridization oven, placing for 4 min on the magnetic stand, and replacing

the wash buffer. During the final wash, 10 μL of beads in the wash buffer were collected for

RNA extraction, Zika-specific RT-qPCR and NGS to analyze the Zika RNA loads, entire virus

genome coverage and NGS depth (see below and results).

For elution, beads were collected on the magnetic stand, resuspended in 600 μL of the ChIRP

biotin elution buffer (12.5 mM biotin # B20656; 7.5 mM HEPES pH 7.9, #AAJ61275AK;

75 mM NaCl, # NC1071140; 1.5 mM EDTA, 0.15% SDS, 0.075% sarkosyl, # NC1386335; and

0.02% Sodium deoxycholate, #AAB2075914; all reagent are from Fisher, MA, USA), rotated at

25°C for 20 min, and at 65°C for 15 min. Beads were placed on the magnetic stand and eluents

were transferred to a fresh tube, and beads were eluted again with 600 μL of the ChIRP biotin

elution buffer. The two eluents were pooled (final 1200 μL) and residual beads were removed

again using the magnetic stand. Afterward, 300 μL of trichloroacetic acid (#T0699; Millipore

Sigma, MA, USA) (25% of the final elute volume) was added to the clean eluent, vortexed, and

placed at 4°C overnight for precipitation. The next day, proteins were pelleted at 21,000 g at 4°C

for 45 min. Supernatants were carefully removed, and protein pellets were washed once with ice-

cold acetone (#A18-1; Fisher, MA, USA). Samples were spun at 21,000 g at 4°C for 5 min.

Acetone was removed, tubes briefly centrifuged again and after removal of residual acetone

tubes were left to air-dry for 1 minute. Then, 60 µL of preheated 1× ChIRP lysis buffer

containing 50 mM TEAB (# PI90114; Fisher, MA, USA) and 5% SDS (# BP2436-200; Fisher,

MA, USA) were added to the protein pellet and gently mixed several times with 200 µL pipette

tips. Samples were immediately put on dry ice and stored in -80°C until sent to the proteomics

facility.

To validate the same viral RNA loads in all samples/experimental conditions at the time of

formaldehyde RNA-protein fixation and ChIRP, RNA extracted during cell lysis (**input**) and

elution steps (**enriched**) (see above) were tested with Zika virus-specific RT-qPCR assay and

NGS to analyze the entire Zika virus genome coverage and NGS depth (**Supplemental Dataset**

1). The Zika virus-specific RT-qPCR assay was conducted as described above. For NGS,

samples were brought to the final volume of 50 µL with 1x PBS and 5 µL Proteinase K

(#FEREO0491; Fisher, MA, USA) and incubated at 55˚C for 30 minutes. Then, RNA was

extracted with the RNA Clean & Concentrator-5 Research Kit (ZYMO) and treated with the

Invitrogen TURBO DNA-free Kit (#AM1907; Fisher, MA, USA). Afterward, 7 µL of RNA was

used to produce cDNA with the Maxima H Minus First Strand cDNA Synthesis Kit

(#FERK1652; Fisher, MA, USA) and random hexamers, following the manufacturer's

instructions. The single stranded cDNA (20 µL) was further used to prepare double-stranded

DNA (dsDNA) using the NEBNext® Second Strand Synthesis (dNTP-free) Reaction Buffer

(#B6117S; NEB, MA, USA) mixed with the DNA Polymerase I (#M0209S; NEB, MA, USA),

E. coli DNA Ligase (#M0205S; NEB, MA, USA), RNase H (#M0297S; NEB, MA, USA),

random hexamers (#N8080127; Fisher, MA, USA), and dNTPs mix (#18427088; Fisher, MA,

USA). The dsDNA was used for library construction with the NEBNext® Ultra II DNA Library

Prep Kit for Illumina (#E7645L; NEB, MA, USA) and NEBNext® Multiplex Oligos for

Illumina® (96 Index Primers) (#E6609S; NEB, MA, USA) as we previously described [7,18,19].

Briefly, the libraries were constructed according to the manufacturer's instructions, with 1:10

adaptor dilution (volume of adaptor:total volume), and following cleanup step of adaptor-ligated

DNA without size selection. Individual libraries were quantified using Qubit dsDNA HS Assay

Kit (#Q32856; Fisher, MA, USA) and Qubit 4.0 Fluorometer (Fisher, MA, USA). The peak size

of the libraries was confirmed with the Agilent DNA 1,000 kit on Agilent 2100 Bioanalyzer

(Agilent, CA, USA). Afterward, 20 ng of each barcoded library were pooled, quantified (Qubit),

quality-checked (Agilent Bioanalyzer), and converted to moles: Molecular weight [nM] =

Library concentration [ng/µL] / (Average library size x 650)/1,000,000). The pooled library was

diluted to 2 nM in 10 mM TE buffer, denatured with 0.1 N NaOH, diluted to 14 pM, and paired-

end 300 nt reads were generated with the MiSeq Reagent kit v3 600 cycle output (Illumina, CA,

USA) on the MiSeq System (Illumina, CA, USA). To compare Zika virus RNA coverage and

NGS depth, FASTQ files representing different samples/experimental conditions were trimmed

for adaptor sequences and filtered for low-quality reads using Trimmomatic. Next, the trimmed

FASTQ paired files were aligned to the Zika virus reference sequence H/PF/2013 [GenBank:

KJ776791.2] using Burrows-Wheeler Aligner (BWA) [20] and output BAM files were used to

quantify and visualize the virus genome coverage and NGS depth with the in-house R script

(https://github.com/itrus/bash-scripts-NGS/tree/main) [7,18,19].

Preparation and mass spectrometry analysis of ChIRP samples were done in The Proteomics

Facility, Network Biology Collaborative Centre, Lunenfeld-Tanenbaum Research Institute,

Toronto. For the S-Trap (ProtiFi, NY, USA) [21,22] the whole volume containing ChIRP-

precipitated proteins were used. The material was reduced with 20 mM DTT for 10 minutes at

+95°C and alkylated with 40 mM iodoacetamide for 30 minutes in the dark. Phosphoric acid was

added to achieve a final concentration of 1.2%. To each 27.5 µl of acidified lysate, 165 µl of S-

Trap protein binding buffer (90% methanol, 100 mM TEAB) was added. The resulting mixture

was passed through the micro column at 4,000 × g, and the column was washed four times with

the S-Trap protein binding buffer. Each sample was digested with 1 µg of trypsin (in 20 µl of 50

mM TEAB) for 1 hour at +47°C. Prior to elution, 40 µl of 50 mM TEAB (pH 8) was added to

the column. Peptides were eluted by centrifugation at 4,000 × g. Peptides were eluted two more

times with 40 µl of 2% formic acid and 40 µl of 50% acetonitrile + 2% formic acid. Eluted

peptides were dried down and stored at -40°C.

For data-dependent acquisition (DDA) LC-MS/MS, digested peptides were analyzed using a

nano-HPLC coupled to MS. Half of the sample was used for DDA. Coated Nano-spray emitters

were generated from fused silica capillary tubing, with 75µm internal diameter, 365µm outer

diameter and 5-8µm tip opening, using a laser puller (Sutter Instrument Co., model P-2000, with

parameters set as heat: 280, FIL = 0, VEL = 18, DEL = 2000). Nano-spray emitters were packed

with C18 reversed-phase material (Reprosil-Pur 120 C18-AQ, 1.9 µm) resuspended in methanol

using a pressure injection cell. The sample in 5% formic acid was directly loaded at 400 nl/min

onto a 75 µm x 15 cm nano-spray emitter. Peptides were eluted from the column with an

acetonitrile gradient generated by an Vanquish Neo UHPLC System and analyzed on an Orbitrap

Fusion Lumos Tribrid. The gradient was delivered at 200 nl/min from 3.2% acetonitrile with

0.1% formic acid to 35.2% acetonitrile with 0.1% formic acid using a linear gradient of 90

minutes. This was followed by a 3 min gradient from 35.2% acetonitrile with 0.1% formic acid

to 79.2% acetonitrile with 0.1% formic acid. Afterward, there was a 5.8 min wash with 79.2%

acetonitrile with 0.1% formic acid, and the column was equilibrated at 400nl/min for 6.4min.

The total DDA protocol was 99 minutes. The MS1 scan had an accumulation time of 50 ms

within a mass range of 400–1500Da, using orbitrap resolution of 120000, 60% RF lens, AGC

target of 125% and 2400 volts. This was followed by MS/MS scans with a total cycle time of 3

seconds. Accumulation time of 50 ms and 33% HCD collision energy was used for each MS/MS

scan. Each candidate ion was required to have a charge state from 2-7 and an AGC target of

400%, isolated using an orbitrap resolution of 15,000. Previously analyzed candidate ions were

dynamically excluded for 9 seconds.

Mass spectrometry RAW data files (**Supplemental Dataset 2**) were converted using

ThermoRawFileParser GUI -V 1.7.1 (https://github.com/compomics/ThermoRawFileParserGUI)

to the mzML format compatible with FragPipe. The RAW files were analyzed using FragPipe

v18.0 (**Supplemental Dataset 2**), which utilized MSFragger v3.5, Philosopher v4.4.0, and

IonQuant for peptide searching in the raw files [23-25]. The LFQ-MBR workflow was used, with

the *Chlorocebus sabaeus* Proteome ID UP000029965

(https://www.uniprot.org/proteomes/UP000029965) database with appended Zika virus

H/PF/2013 [GenBank: KJ776791.2], decoys, and contaminants sequences. Data from the output

"combined_protein.tsv" file (**Table S1B; Supplemental Dataset 2**) were used for interactome

analysis described below.

Identification of Extended, ZAP-independent, and ZAP-dependent Zika virus RNA

interactomes from ChIRP-MS results

The Zika virus RNA-interacting proteins were scored with the Mass spectrometry interaction

STatistics (MiST) analysis which was previously applied for ChIRP-MS [17,26,27]. We used

MiST default parameters; for specificity, we also selected the Singleton Filtering MiST option to

exclude proteins with spectral counts in only one biological replicate and quantify proteins with

MiST score 0.75 or above [17,26,27]. We also excluded all proteins which had at least a single

spectral count in at least one of biological replicate in mock-infected wild-type or ZAP-KO cells

[17,28].

We applied three analytical strategies to examine ChIRP-MS data. For the first analytical

strategy, using the raw ChIRP-MS data with total 2,269 proteins (**Table S1B)**, we identified

proteins specifically associated with Zika virus RNA in VERO-ZAP-WT cells. We defined the

resultant list of enriched proteins as "extended" Zika virus RNA interactome in VERO-ZAP-WT

cells. For the second analytical strategy, we identified proteins specifically interacting with Zika

virus RNA in VERO-ZAP-KO cells. We defined the resultant list of enriched proteins as "ZAP-

independent" Zika virus RNA interactome. We defined this interactome as ZAP-independent

because associated cellular proteins were discovered in VERO-ZAP-KO cells which shows

ZAP-independent nature of interactions. Finally, for the discovery of "ZAP-dependent" Zika

RNA interactome in VERO-ZAP-WT cells, in addition to the above specificity exclusion criteria

in MiST settings and in mock-infected cells, we excluded proteins which had at least one spectral

count in at least one of the biological replicates in VERO-ZAP-KO cells infected with Zika

virus.

For ZAP-independent and ZAP-dependent Zika virus RNA interactomes, we performed GO

enrichment analyses of the identified proteins using The Gene Ontology Resource

(https://geneontology.org/) which connects to the analysis tool from the PANTHER

Classification System [29-31]. For analysis, GO aspect molecular function was selected. As

recommended, a custom reference list containing all proteins' IDs identified in the specific mass

spectrometry run (**Tables S1B**) was added after initial analysis on The Gene Ontology Resource

and the analysis was re-run on the PANTHER website. The significance P values of GO terms

were calculated by Fisher's exact test and adjusted by FDR.

Statistics

We used GraphPad PRISM 9 software. For the comparison of the number of virus-positive cell

counts, and viral RNA loads between wild-type and ZAP-KO cells we used an unpaired t-test.

For the comparison of Western blot protein expression, we used one-way ANOVA multiple

comparisons. P-value < 0.05 was considered statistically significant.

SUPPLEMENTAL REFERENCES

1. Nguyen Phuong Khanh Le PPS, Ahmad Jawad Sabir, Ivan Trus, Uladzimir Karniychuk. Endogenous ZAP is associated with altered global cellular gene expression during Zika virus infection. bioRxiv. 2024. https://doi.org/10.1101/2024.05.23.595518

2. Trus I, Udenze D, Berube N, et al. CpG-Recoding in Zika Virus Genome Causes Host-Age-Dependent Attenuation of Infection With Protection Against Lethal Heterologous Challenge in Mice. Front Immunol. 2019;10:3077.

3. Trus I, Berube N, Jiang P, et al. Zika Virus with Increased CpG Dinucleotide Frequencies Shows Oncolytic Activity in Glioblastoma Stem Cells. Viruses: Multidisciplinary Digital Publishing Institute; 2020. p. 579.

4. Udenze D, Trus I, Berube N, et al. The African strain of Zika virus causes more severe in utero infection than Asian strain in a porcine fetal transmission model. Emerging Microbes & Infections. 2019; 8:1098-1107.2019.

5. Darbellay J, Cox B, Lai K, et al. Zika Virus Causes Persistent Infection in Porcine Conceptuses and may Impair Health in Offspring. EBioMedicine. 25:73-86.2017.

6. Chapagain S, Pal Singh P, Le K, et al. Japanese encephalitis virus persists in the human reproductive epithelium and porcine reproductive tissues. PLoS Negl Trop Dis. 2022 Jul;16(7):e0010656.

7. Sabir AJ, Singh PP, Trus I, et al. Asian Zika virus can acquire generic African-lineage mutations during in utero infection. Emerg Microbes Infect. 2023 Dec;12(2):2263592.

8. Darbellay J, Lai K, Babiuk S, et al. Neonatal pigs are susceptible to experimental Zika virus infection. Emerg Microbes Infect. 2017 Feb 15;6(2):e6.

9. Trus I, Udenze D, Cox B, et al. Subclinical in utero Zika virus infection is associated with interferon alpha sequelae and sex-specific molecular brain pathology in asymptomatic porcine offspring. In: Pierson TC, editor. PLoS Pathogens2019. p. e1008038.

10. Trus I, Darbellay J, Huang Y, et al. Persistent Zika virus infection in porcine conceptuses is associated with elevated <i>in utero</i> cortisol levels. Virulence2018. p. 21505594.2018.1504558.

11. Xu MY, Liu SQ, Deng CL, et al. Detection of Zika virus by SYBR green one-step real-time RT-PCR. Journal of virological methods: J Virol Methods; 2016. p. 93-97.

12. Eiden M, Vina-Rodriguez A, Hoffmann B, et al. Two new real-time quantitative reverse transcription polymerase chain reaction assays with unique target sites for the specific and sensitive detection of lineages 1 and 2 West Nile virus strains. J Vet Diagn Invest. 2010 Sep;22(5):748-53.

13. Shao N, Li F, Nie K, et al. TaqMan Real-time RT-PCR Assay for Detecting and Differentiating Japanese Encephalitis Virus. Biomedical and environmental sciences : BES: Biomed Environ Sci; 2018. p. 208-214.

14. Chu C, Zhang QC, da Rocha ST, et al. Systematic discovery of Xist RNA binding proteins. Cell. 2015 Apr 9;161(2):404-16.

15. Flynn RA, Belk JA, Qi Y, et al. Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. Cell. 2021 Apr 29;184(9):2394-2411 e16.

16. Ooi YS, Majzoub K, Flynn RA, et al. An RNA-centric dissection of host complexes controlling flavivirus infection. Nat Microbiol. 2019 Dec;4(12):2369-2382.

17. Zhang S, Huang W, Ren L, et al. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 2022 Jan;32(1):9-23.

18.   Udenze D, Trus I, Berube N, et al. CpG content in the Zika virus genome affects infection
phenotypes in the adult brain and fetal lymph nodes. Front Immunol. 2022;13:943481.
19.   Udenze D, Trus I, Munyanduki H, et al. The isolated in utero environment is conducive to the
emergence of rna and dna virus variants. Viruses: Multidisciplinary Digital Publishing Institute;
2021. p. 1827.
20.   Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
Bioinformatics. 2009 Jul 15;25(14):1754-60.
21.   Bang G, Lee H, Kim H, et al. Comparison of protein characterization using In solution and S-Trap
digestion methods for proteomics. Biochem Biophys Res Commun. 2022 Jan 22;589:197-203.
22.   HaileMariam M, Eguez RV, Singh H, et al. S-Trap, an Ultrafast Sample-Preparation Approach for
Shotgun Proteomics. J Proteome Res. 2018 Sep 7;17(9):2917-2924.
23.   Yu F, Haynes SE, Teo GC, et al. Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger
and IonQuant. Mol Cell Proteomics. 2020 Sep;19(9):1575-1585.
24.   da Veiga Leprevost F, Haynes SE, Avtonomov DM, et al. Philosopher: a versatile toolkit for
shotgun proteomics data analysis. Nat Methods. 2020 Sep;17(9):869-870.
25.   Kong AT, Leprevost FV, Avtonomov DM, et al. MSFragger: ultrafast and comprehensive peptide
identification in mass spectrometry-based proteomics. Nat Methods. 2017 May;14(5):513-520.
26.   Verschueren E, Von Dollen J, Cimermancic P, et al. Scoring Large-Scale Affinity Purification Mass
Spectrometry Datasets with MiST. Curr Protoc Bioinformatics. 2015 Mar 9;49:8 19 1-8 19 16.
27.   Jager S, Cimermancic P, Gulbahce N, et al. Global landscape of HIV-human protein complexes.
Nature. 2011 Dec 21;481(7381):365-70.
28.   Goodier JL, Pereira GC, Cheung LE, et al. The Broad-Spectrum Antiviral Protein ZAP Restricts
Human Retrotransposition. PLOS Genetics: Public Library of Science; 2015. p. e1005252.
29.   The Gene Ontology C. Expansion of the Gene Ontology knowledgebase and resources. Nucleic
Acids Res. 2017 Jan 4;45(D1):D331-D338.
30.   Mi H, Muruganujan A, Huang X, et al. Protocol Update for large-scale genome and gene function
analysis with the PANTHER classification system (v.14.0). Nat Protoc. 2019 Mar;14(3):703-721.
31.   Mi H, Muruganujan A, Ebert D, et al. PANTHER version 14: more genomes, a new PANTHER GO-
slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019 Jan 8;47(D1):D419-
D426.

Fig S2. VERO-ZAP-WT and VERO-ZAP-KO cells genotyped with Sanger sequencing as described in Supplemental Materials and Methods. Location of indels on *Chlorocebus sabaeus* genome: -2bp deletion, NW_023666072.1: 4677550-4677551.

Fig S3. ZAP Western blot. (A) ZAP Western blot in VERO-ZAP-KO and VERO-ZAP-WT cells.
Cells were mock infected or infected with normalized Zika virus MOIs; MOI 2 or 10 for VERO-
ZAP-KO and VERO-ZAP-WT cells, respectively, as described for ChIRP in supplemental
materials and methods. Cells were sampled at 72 h after mock or virus infection. Green bands
represent ZAP with the manufacturer's predicted size 111 kDa; multiple bands may represent four
isoforms described for human ZAP [1] and still not experimentally characterized for monkeys.
Red bands represent β-actin loading control, 42 kDa. Western blot was done in 3 biological
replicates for each experimental condition. **(B)** The expression of ZAP was quantified as described
in supplemental material and methods.

Fig S4. The Zika RNA genome coverage and NGS depth in VERO-ZAP-WT and VERO-ZAP-KO cells. **Input** - sonicated cellular lysates. **Enriched** - immunoprecipitated viral RNA-protein complexes bound to MyOne C1 magnetic beads at the last washing step before protein elution. Control NGS in mock-infected cells did not show Zika-specific sequences. A red line shows the 10-nucleotide NGS depth threshold.

VERO-WT

72 hours

1 hour

Bio replicate #1

Mock

JEV

Bio replicate #2

Mock

JEV

Bio replicate #3

Mock

JEV

S1FigA

VERO-ZAP-KO

72 hours

1 hour

Bio replicate #1

Mock

JEV

Bio replicate #2

Mock

JEV

Bio replicate #3

Mock

JEV

S1FigB

VERO-WT

72 hours

1 hour

Bio replicate #1

Mock

Zika

Bio replicate #2

Mock

Zika

Bio replicate #3

Mock

Zika

S1FigC

VERO-ZAP-KO

72 hours

1 hour

Bio replicate #1

Mock

Zika

Bio replicate #2

Mock

Zika

Bio replicate #3

Mock

Zika

S1FigD

VERO-WT

1 hour

48 hours
Bio replicate #1

Mock

WNV

Bio replicate #2

Mock

WNV

Bio replicate #3

Mock

WNV

S1FigE

VERO-ZAP-KO

48 hours

1 hour

Bio replicate #1

Mock

WNV

Bio replicate #2

Mock

WNV

Bio replicate #3

Mock

WNV

S1FigF